Expression of topoisomerase II alpha, Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation

被引:9
作者
Horibe, Y
Murakami, M
Komori, K
Imaeda, Y
Kasahara, M
机构
[1] Fujita Hlth Univ, Sch Med, Dept Otolaryngol, Aichi 4701192, Japan
[2] Fujita Hlth Univ, Sch Med, Inst Pathol, Toyoake, Aichi 47011, Japan
[3] Fujita Hlth Univ, TEaching Hosp 2, Clin Lab, Dept Pathol, Toyoake, Aichi 47011, Japan
关键词
topoisomerase II alpha; Ki-67; p53; immunohistochemistry; squamous cell carcinoma; larynx;
D O I
10.1034/j.1600-0463.2000.d01-16.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aim. To determine whether topoisomerase II alpha (topoIIa) expression is an additional prognostic marker for less advanced stage laryngeal cancers first treated without surgery. Ki-67 and p53 protein levels were also assessed for comparison. Experimental design. Formalin-fixed, paraffin-embedded tumor material from 63 cases of squamous cell carcinoma (SCC) of the larynx (glottis, stages 0,1,2) was immunohistochemically stained for topoIIa, Ki-67 (MIB-1) and p53 (DO-7) and the results were compared with clinicopathologic findings. Results. There were 7 stage 0 (TisN0M0), 33 stage I (T1N0M0), and 23 stage II (T2N0M0) SCCs with the TNM classification. Significant differences between carcinomas and normal mucosa were found for the topoIIa-LI, Ki-67-LI, and topoIIa-to-Ki-67 ratio. Regarding histologic grade, a significant difference in topoIIa-to-Ki-67 ratio was evident between well or moderately and poorly differentiated lesions. There were 19 cases of recurrence and 44 cases of nonrecurrence, but no significant differences were found for either of the indices or their ratio. No significant variation with p53 positivity was evident with reference to histologic differentiation, T-factor, clinical course, or proliferation. Conclusions. The results demonstrate that the topoIIa-to-Ki-67 ratio is a more sensitive parameter reflecting proliferation, for histologic grading of less advanced laryngeal SCCs, than topoIIa- or Ki-67-LIs.
引用
收藏
页码:689 / 696
页数:8
相关论文
共 43 条
[1]  
AUSTIN DF, 1982, CANCER EPIDEMIOL, P554
[2]  
BEAHRS OH, 1988, MANUAL STAGING CANCE, P39
[3]  
Brambilla E, 1996, AM J PATHOL, V149, P1941
[4]   IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CLINICAL ONCOLOGY [J].
CHANG, FJ ;
SYRJANEN, S ;
SYRJANEN, K .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :1009-1022
[5]  
CHOU MY, 1990, AM J PATHOL, V136, P729
[6]  
COON JS, 1987, LAB INVEST, V57, P453
[7]   A P53-DEPENDENT MOUSE SPINDLE CHECKPOINT [J].
CROSS, SM ;
SANCHEZ, CA ;
MORGAN, CA ;
SCHIMKE, MK ;
RAMEL, S ;
IDZERDA, RL ;
RASKIND, WH ;
REID, BJ .
SCIENCE, 1995, 267 (5202) :1353-1356
[8]  
DRAKE FH, 1987, J BIOL CHEM, V262, P16739
[9]  
Dunphy CH, 1997, ARCH OTOLARYNGOL, V123, P1223
[10]  
GERDES J, 1984, J IMMUNOL, V133, P1710